Neurophth Ranked as One of the MIT 50 Smartest Companies 2021
Source:   Release Date: 2022-07-29

WUHAN and SAN DIEGO, Jul. 29, 2022 – MIT Technology Review released the MIT 50 Smartest Companies (TR50) of the year 2021. Neurophth Therapeutics, Inc., (“Neurophth”) is one of the award winners.

MIT Technology Review has picked “50 Smart Companies” from thousands of technology companies around the world to share its insights into the future of technology each year since 2010. The 50 Smartest Companies list was created to recognize companies that best combine innovative technology with an effective business model. It demonstrates the innovative breakthroughs and the significant impact that emerging technologies bring to China and the world.

Neurophth is China’s leading in-vivo gene therapy company for ophthalmic diseases. With subsidiaries in China (Wuhan, Shanghai, and Suzhou) and US (San Diego, California), Neurophth, a fully integrated company, is striving to discover and develop genomic medicines for patients suffering from genetic diseases globally. Our validated AAV platform, which has been published in Nature - Scientific Reports, Ophthalmology, and EBioMedicine, has successfully delivered proof-of-concept investigator-initiated trials data of 186 subjects with investigational gene therapies in the retina.

Our most advanced investigational gene therapy drug candidate, NR082 (rAAV2-ND4), in development for the treatment of mtND4-mediated LHON, has been granted orphan drug designation (ODD) by the U.S. FDA and EMA. After the IND clearance by the China NMPA in March 2021 and the U.S. IND by FDA in January 2022, Neurophth has successfully completed an EOP2 meeting with CDE and reached an agreement on the design of the Phase III clinical trial. The pipeline also includes mtND1-mediated LHON (the Company’s 2nd US ODD), autosomal dominant optic atrophy, optic neuroprotection, vascular retinopathy, and five other preclinical candidates. Neurophth has scaled up in-house manufacturing capability in Suzhou facility utilizing single-use technologies to support future commercial demand. To learn more about us and our growing pipeline, visit